Experience

Davis Polk advised the joint book-running managers in connection with the $86.3 million initial public offering of common stock of Dova Pharmaceuticals, Inc. The common stock is listed on…

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the $75 million initial public offering of common stock of Mersana Therapeutics…

Davis Polk is advising J.P. Morgan Securities LLC as financial adviser to Bankrate, Inc. in connection with its acquisition at an enterprise value of approximately $1.4 billion by Red…

On June 29, 2017, Davis Polk achieved a total victory in a litigation filed in New York state court against its client Consolidated Edison, Inc.The case against Con Edison, captioned …

Davis Polk advised the joint book-running managers on an SEC-registered offering by General Motors Financial Company, Inc. of $500 million aggregate principal amount of floating-rate senior…

Davis Polk advised Compass Bank, a wholly owned subsidiary of BBVA Compass Bancshares, Inc., in connection with the offering of $750 million aggregate principal amount of its 2.875% senior…

Davis Polk advised the joint lead managers in connection with the $600 million Regulation S offering by Shui On Development (Holding) Limited of its 6.40% senior perpetual capital…

Davis Polk is advising Dyal Capital Partners, a division of Neuberger Berman Group, on its strategic minority investment in Atalaya Capital Management. Dyal will become a passive, non…

Davis Polk advised the representative of the several underwriters in connection with a secondary offering of 4,500,000 shares of Class A common stock of Evolent Health, Inc. by certain of…

Davis Polk is advising J.P. Morgan Securities LLC as financial adviser to The Spectranetics Corporation in connection with its acquisition by a wholly owned subsidiary of Royal Philips,…